Approved for use through 06/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	Docket Number (Optional) DPP4-5004-C2
In re Application of: Jun Feng et al.	
Application No.: 10/809,637	
Filed: March 24, 2004	
For: DIPEPTIDYL PEPTIDASE INHIBITORS	
The owner*, TAKEDA PHARMACEUTICAL COMPANY LIMITED, of	ation which would extend beyond 10/809,635 , filed atent granted on said reference reference application. The owner such period that it and any patent
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on t extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any part application, "as the term of any patent granted on said reference application may be shortened by any terminated of any patent on the pending reference application," in the event that: any such patent: granted on the pexpires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent juin whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to	Itent granted on said reference minal disclaimer filed prior to the pending reference application: risdiction, is statutorily disclaimed , is reissued, or is in any manner
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, gove etc.), the undersigned is empowered to act on behalf of the business/organization.	rnment agency,
I hereby declare that all statements made herein of my own knowledge are true and that all state belief are believed to be true; and further that these statements were made with the knowledge that willful made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States statements may jeopardize the validity of the application or any patent issued thereon.	false statements and the like so
2. The undersigned is an attorney or agent of record. Reg. No. 38,394	
Mitchell R Brust	June 19, 2008
Signature	Date
Mitchell R. Brustein Typed or printed name	
	858-622-8528 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information s be included on this form. Provide credit card information and authorization on P	

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).